Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing medicines that target the melanocortin receptor (MCR) system, today announced financial results for its fiscal third quarter ended March 31, 2026, and provided a business update.Read More
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
By PR Newswire
